Blue Cross and Blue Shield of Texas (BCBSTX) — a Division of Health Care Service Corporation (HCSC) — is the largest health insurer in Texas, serving over 6 million members across commercial, Medicare Advantage, Medicaid, and marketplace plans. BCBSTX contracts with Prime Therapeutics for pharmacy benefit management, and GLP-1 receptor agonist coverage varies significantly by plan type, employer group elections, and formulary tier.
In Spring 2026, BCBSTX announced updates reflecting the rapidly evolving GLP-1 landscape: Ozempic tablets replacing Rybelsus, Wegovy HD added to formularies, Foundayo (orforglipron) tablets as a new FDA-approved option, and Zepbound Kwikpen excluded from coverage. This guide maps which GLP-1 medications BCBSTX covers under which diagnoses, details PA criteria and supply limits, and explains common denial reasons. It is independent information and not medical advice or reimbursement guidance for a specific patient or plan.
Quick answer
| GLP-1 Drug | BCBSTX Commercial (Employer Groups) | BCBSTX Marketplace (ACA) | BCBSTX Medicare Advantage |
|---|---|---|---|
| Ozempic (semaglutide injection) | Covered — T2D with PA | Covered — T2D with PA | Covered — T2D with PA |
| Ozempic Tablets (semaglutide oral) | Covered — T2D with PA (replacing Rybelsus) | Covered — T2D with PA | Covered — T2D with PA |
| Mounjaro (tirzepatide injection) | Covered — T2D with PA | Covered — T2D with PA | Covered — T2D with PA |
| Trulicity (dulaglutide) | Covered — T2D with PA | Covered — T2D with PA | Covered — T2D with PA |
| Rybelsus (semaglutide tablets) | Being replaced by Ozempic Tablets per Spring 2026 update | Being replaced by Ozempic Tablets | Being replaced by Ozempic Tablets |
| Wegovy (semaglutide 2.4 mg) | Covered for weight loss on select employer groups with PA; covered for CVD/MASH | Not covered for weight loss (most metallic plans) | Covered for CVD and MASH with PA per CMS rules |
| Wegovy HD (semaglutide 7.2 mg) | Added to formularies Spring 2026; PA required | Added Spring 2026; PA required | Added Spring 2026; PA required |
| Zepbound (tirzepatide) | Covered for weight loss on select employer groups with PA | Not covered for weight loss (most metallic plans) | Covered for OSA with PA |
| Zepbound Kwikpen | Excluded from coverage per Spring 2026 update | Excluded | Excluded |
| Saxenda (liraglutide 3 mg) | Covered on select plans with PA | Not typically covered | PA required |
| Foundayo (orforglipron tablets) | New FDA-approved option added Spring 2026; PA status pending formulary review | Pending formulary review | Pending formulary review |
Key policy dates:
- April 1, 2024: BCBSTX launched optional GLP-1 "New to Therapy" benefit program limiting initial fills to 30-day supplies for select commercial members through Prime Therapeutics
- October 2024: 30-day supply limit program expanded to cover all GLP-1 and anti-obesity drugs for select commercial members
- January 1, 2026: Updated formulary and PA criteria took effect across all plan types
- May 20, 2026: Spring 2026 GLP-1 coverage update announced — Ozempic tablets replace Rybelsus, Wegovy HD added, Foundayo introduced, Zepbound Kwikpen excluded
Who this is for
- BCBSTX commercial members and their prescribers navigating GLP-1 prior authorization
- Marketplace (ACA) plan members seeking to understand which GLP-1s are covered on metallic plans
- Benefit verification specialists and hub teams handling BCBSTX pharmacy claims
- Market access teams at GLP-1 manufacturers tracking Texas-specific payer policy
- Employer benefits administrators evaluating BCBSTX GLP-1 coverage options for Texas employees
Source standard
Every fact in this guide is sourced from BCBSTX provider communications, BCBSTX employer newsletters, Prime Therapeutics formulary documents, and HCSC/BCBSTX drug lists dated 2024–2026. BCBSTX coverage rules vary by plan, employer group, and formulary. Always verify current coverage by calling the member services number on your BCBSTX card or checking Blue Access for Members at bcbstx.com.
BCBSTX structure and GLP-1 relevance
BCBSTX is a Division of Health Care Service Corporation (HCSC), which also operates BCBS plans in Illinois, Montana, New Mexico, and Oklahoma. Key structural features relevant to GLP-1 coverage:
- Pharmacy benefit manager: Prime Therapeutics manages pharmacy benefits for BCBSTX commercial and marketplace plans. BCBSTX and several independent BCBS plans have an ownership interest in Prime Therapeutics
- Formulary structure: BCBSTX uses multiple formularies — Basic, Enhanced, Multi-Tier Basic, Multi-Tier Enhanced, and Health Insurance Marketplace formularies — each with different GLP-1 tier placements and PA requirements
- Specialty pharmacy: Accredo is the contracted specialty pharmacy for BCBSTX members requiring specialty medications including GLP-1 injectables
- Employer group optionality: GLP-1 weight-loss coverage is primarily determined by employer group election. BCBSTX does not universally cover GLP-1s for weight loss; it depends on whether the employer group has selected this benefit
Formulary placement by drug
Diabetes-indicated GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus/Ozempic Tablets)
These medications are on BCBSTX formularies for type 2 diabetes with prior authorization. Key requirements:
- Diagnosis requirement: PA requires documented diagnosis of type 2 diabetes mellitus (ICD-10 E11.x)
- Step therapy: Some formularies require trial of metformin before GLP-1 approval
- Quantity limits: 30-day supply limits apply for select commercial members under the GLP-1 supply management program
- Smart PA: BCBSTX coordinates real-time medical and pharmacy claims data to streamline PA reviews for diabetes-indicated GLP-1s, enabling faster approvals when medical claims confirm a T2D diagnosis
Spring 2026 update: Ozempic Tablets replace Rybelsus
BCBSTX announced in May 2026 that Ozempic tablets (oral semaglutide) are replacing Rybelsus on formularies. This follows the FDA approval and market launch of Ozempic tablets, which supersede the older Rybelsus brand for the same oral semaglutide therapy.
Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda)
Coverage for weight-loss GLP-1s on BCBSTX plans is heavily dependent on employer group benefit design:
- Self-funded employer groups: May elect GLP-1 weight-loss coverage. BCBSTX's GLP-1 white paper describes strategies to help employers manage costs while providing access
- Fully insured commercial plans: Coverage varies. Many smaller group plans do not include GLP-1 weight-loss benefits
- Marketplace (ACA) plans: Most BCBSTX metallic plans (platinum, gold, silver, bronze) do not cover GLP-1s for weight loss. The BCBSTX Connect Community FAQ confirms that "most plans don't cover GLP-1s for weight loss"
- Medicare Advantage: Wegovy covered for cardiovascular disease and MASH indications per CMS rules; Zepbound covered for obstructive sleep apnea
Wegovy formulary details
On the BCBSTX Multi-Tier Basic Drug List (updated April 1, 2026):
| Wegovy Formulation | PA Required | Quantity Limit |
|---|---|---|
| Auto-injector 0.25/0.5/1 mg | Yes | 8 pens per 180 days |
| Auto-injector 1.7/2.4 mg | Yes | 4 pens per 28 days |
| Tablet 1.5/4/9 mg | Yes | 60 tablets per 180 days |
| Tablet 25 mg | Yes | 30 tablets per 30 days |
Zepbound formulary details
| Zepbound Formulation | PA Required | Quantity Limit |
|---|---|---|
| Auto-injector 2.5 mg | Yes | 4 pens per 180 days |
| Auto-injector 5/7.5/10/12.5/15 mg | Yes | 4 pens per 28 days |
| Zepbound Kwikpen | Excluded | Not covered |
30-day supply limit program
BCBSTX implemented an optional pharmacy benefit program effective October 2024 that limits GLP-1 and anti-obesity drug fills to 30-day supplies for select commercial members. The program covers:
- Affected drugs: Mounjaro, Ozempic, Orlistat, Phentermine HCL, Qsymia, Saxenda, Trulicity, Wegovy, and Zepbound
- Employer group option: This is an optional program that employers select. Not all BCBSTX commercial members are subject to this limit
- Rationale: BCBSTX implemented this to reduce drug waste and cost associated with GLP-1 therapy, noting that GLP-1s have a "relatively high rate of drop-off in utilization" and removing them from 90-day maintenance drug lists ensures members are actively using the medication before filling larger supplies
Prior authorization criteria
For type 2 diabetes
BCBSTX PA criteria for diabetes-indicated GLP-1s typically require:
- Confirmed T2D diagnosis: Documented via ICD-10 E11.x codes on medical claims
- Prior therapy documentation: Some plans require trial and failure of metformin or other first-line agents
- A1C documentation: BCBSTX has evolved PA criteria to gather additional information including A1C levels to ensure appropriate use
- Quantity limits: 30-day supply for select members
For weight loss (where covered)
When an employer group elects GLP-1 weight-loss coverage, PA criteria typically include:
- BMI threshold: BMI ≥ 30 kg/m² (obesity), or BMI ≥ 27 kg/m² with weight-related comorbidity
- Prior therapy: Some plans require trial of lifestyle modification or other weight-loss medications
- Clinical documentation: Diagnosis codes, weight history, and comorbidity documentation
- Renewal requirements: Continued coverage may require documentation of weight-loss response
PA submission and turnaround
- Standard review: Up to 10 business days for BCBS plans to make a final decision
- Expedited review: Available if a health condition may jeopardize life, health, or ability to regain function. BCBSTX will provide a coverage decision within 24 hours of receiving the expedited request
- Submission: Prescribers can submit PA requests through the Blue Access for Providers portal or by calling the number on the member's BCBSTX ID card
Common denial reasons and appeal steps
Common denials
- Weight-loss GLP-1 not a covered benefit: The employer group did not elect GLP-1 weight-loss coverage. This is the most common reason for denial on BCBSTX commercial plans
- Missing T2D diagnosis: PA submitted without documented type 2 diabetes diagnosis codes
- Step therapy not met: Required prior therapy (metformin, etc.) not documented
- Quantity limit exceeded: Prescription written for more than 30-day supply under applicable programs
- Zepbound Kwikpen excluded: Per Spring 2026 update, the Kwikpen formulation is specifically excluded
Appeal process
- Prescriber appeal: The prescribing healthcare provider can submit an appeal explaining medical necessity
- Formulary exception request: If a drug is not on the member's formulary, the member or prescriber can request a coverage exception through BCBSTX
- Expedited review: Available for urgent clinical situations
- Alternative medications: If denied, BCBSTX will typically suggest covered alternatives
BCBSTX vs. other Texas BCBS plans
BCBSTX is the Texas licensee of the Blue Cross Blue Shield Association. Members should not confuse BCBSTX with:
- Blue Cross Blue Shield of Illinois (BCBSIL): Separate HCSC division with different formulary decisions
- FirstCare Health Plans: A BCBSTX subsidiary that manages STAR Medicaid and CHIP plans in Texas
- Scott and White Health Plan: Now part of BCBSTX network but may have different formulary rules
What to monitor next
- Foundayo (orforglipron) formulary placement: BCBSTX has identified this as a new FDA-approved option but formulary tier and PA criteria are still being determined
- Wegovy HD coverage expansion: The 7.2 mg dose was added to formularies in Spring 2026; monitor for PA criteria updates
- Employer group renewal cycle: GLP-1 weight-loss coverage may change at employer group renewal — always verify at renewal
- State legislative action: Texas legislature may consider GLP-1 coverage mandates in upcoming sessions
- Zepbound new formulations: If Eli Lilly introduces alternatives to the Kwikpen, coverage may be revisited
Sources
- FDA. "FDA Approves New Indication for Wegovy (semaglutide) Injection to Reduce Risk of Major Cardiovascular Events." fda.gov, March 8, 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-approves-new-indication-wegovy-semaglutide-injection-reduce-risk-major-cardiovascular-events
- CMS. "Medicare Drug Price Negotiation Program: Selected Drugs for 2027." cms.gov, January 2025. https://www.cms.gov/informational-materials-selected-drugs-negotiated-prices-2027
- Blue Cross and Blue Shield of Texas. "What's New in GLP-1 Coverage – Spring 2026." bcbstx.com, May 20, 2026. https://bcbstx.com/producer/news/05-20-26-new-glp1-coverage-2026
- Blue Cross and Blue Shield of Texas. "30-Day Supply Limit: Select Commercial Members Have New Pharmacy Benefit for GLP-1 and/or Anti-Obesity Drug Therapy." bcbstx.com, October 2024. https://www.bcbstx.com/provider/education/education/news/2024/10-04-24-pharmacy-supply-limit-glp1-obesity
- Blue Cross and Blue Shield of Texas. "GLP-1 New to Therapy Optional Benefit Program Available for Select Commercial Members." bcbstx.com, June 2024. https://www.bcbstx.com/provider/education/education/news/2024/06-07-2024-glp-new-therapy-optional-benefit-pgrm-select-comm-members
- Blue Cross and Blue Shield of Texas. "GLP-1 White Paper." bcbstx.com. https://www.bcbstx.com/docs/employer/tx/glp1-white-paper-grp-emp-prod-tx.pdf
- Blue Cross and Blue Shield of Texas. Multi-Tier Basic Drug List, Updated April 1, 2026. https://www.bcbstx.com/tx/documents/rx-drugs/drug-lists/multi-basic-tx-2026.pdf
- Prime Therapeutics. "Commercial Formularies & Drug Guides." primetherapeutics.com. https://www.primetherapeutics.com/commercial-formularies
- Blue Cross and Blue Shield of Texas. "GLP-1s for Weight Loss – Ask BCBSTX." connect.bcbstx.com. https://connect.bcbstx.com/ask-bcbstx/w/frequently-asked-questions/322/glp-1s-for-weight-loss
